Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.44 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29868206 | 0.91 | CTRB1 (0.56) | CTRB1OPRM1OPRD1OPRK1CMA1 | |
| SCHEMBL6434028 | 0.91 | CTRB1 (0.56) | CTRB1OPRM1OPRD1OPRK1CMA1 | |
| SCHEMBL24414053 | 0.91 | OPRM1 (0.47) | CTRB1OPRM1OPRD1OPRK1CMA1 | |
| SCHEMBL30165246 | 0.91 | CMA1 (0.50) | OPRM1OPRD1OPRK1CMA1SLC6A2 | |
| SCHEMBL30429187 | 0.89 | CTRB1 (0.51) | CTRB1OPRM1OPRD1OPRK1CMA1 | |
| SCHEMBL11947977 | 0.86 | CTRB1 (0.55) | CTRB1OPRM1OPRD1OPRK1CMA1 | |
| SCHEMBL29749447 | 0.84 | CTRB1 (0.48) | CTRB1KMT2A | |
| SCHEMBL29858987 | 0.83 | CTRB1 (0.46) | CTRB1CMA1KMT2A | |
| SCHEMBL29706288 | 0.83 | CTRB1 (0.55) | CTRB1KMT2A | |
| SCHEMBL29566581 | 0.82 | CTRB1 (0.46) | CTRB1KMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4509517-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-19 | — | — | EP | disclosed |
| US-20230391818-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-07 | — | — | US | disclosed |
| EP-4242219-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391818-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, DNPEP, NPPA | CTRB1 2754/4885OPRM1 4428/4885OPRD1 4318/4885 |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, NPPA, DNPEP | CTRB1 3178/4885OPRM1 4525/4885OPRD1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.